The potential of tetrandrine against gliomas

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 7, 2010, Pages 534-542

  Chen, Yun ^a,b   Tseng, Sheng Hong ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b YUAN ZE UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Anticancer effect; Glioma; Tetrandrine

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PACLITAXEL; REACTIVE OXYGEN METABOLITE; TETRANDRINE; VERAPAMIL; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER GRADING; CARDIOTOXICITY; CELL CYCLE ARREST; CLINICAL TRIAL; COLON CANCER; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TRANSPORT; EHRLICH ASCITES TUMOR; ENZYME ACTIVITY; GLIOMA; GLIOMA CELL; HUMAN; HYDROPHOBICITY; LIPID SOLUBILITY; LIVER TOXICITY; LUNG TOXICITY; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RADIOSENSITIZATION; SARCOMA; STEPHANIA TETRANDRA;

EID: 78649875624     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010793498609     Document Type: Article

References (102)

1. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHOClassification of Tumors of the Central Nervous System, IARCPress: Lyon, France, 2007.
2. Brandsma, D.; van der Bent, M.J. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr. Opin. Oncol., 2007, 19(6), 598-605.
3. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med.2008, 359(5), 492-507.
4. Hochberg, F.H.; Pruitt, A. Assumptions in the radiotherapy of glioblastomas. Neurology, 1980, 30(9), 907-911.
5. Selker, R.G.; Shapiro, W.R.; Burger, P.; Blackwood, M.S.; Arena, V.C.; Gilder, J.C.; Malkin, M.G.; Mealey, J.J. Jr.; Neal, J.H.; Olson, J.; Robertson, J.T.; Barnett, G.H.; Bloomfield, S.; Albright, R.; Hochberg, F.H.; Hiesiger, E.; Green, S.; Brain Tumor CooperativeGroup. The Brain Tumor Cooperative Group NIH Trial 87-01: arandomized comparison of surgery, external radiotherapy, and carnustineversus surgery, interstitial radiotherapy boost, external radiationtherapy, and carmustine. Neurosurgery, 2002, 51(2), 343-355.
6. Tsao, M.N.; Mehta, M.P.; Whelan, T.J.; Morris, D.E.; Hayman, J.A.; Flickinger, J.C.; Mills, M.; Rogers, C.L.; Souhami, L. TheAmerican Society for Therapeutic Radiology and Oncology (ASTRO)evidence-based review of the role of radiosurgery for malignantglioma. Int. J. Radiat. Oncol. Biol. Phys., 2005, 63(1), 47-55.
7. Yamanaka, R.; Saya, H. Molecularly targeted therapies for glioma.Ann. Neurol., 2009, 66(6), 717-729.
8. Hegi, M.E.; Diserena, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.; Hau, P.; Mirimanoff, R.O.; Cairncross, J.G.; Janzer, R.C.; Stupp, R. MGMT gene silencing and benefit fromtemozolomide in glioblastoma. N. Engl. J. Med., 2005, 352(10), 997-1003.
9. Sathornsumetee, S.; Reardon, D.A.; Desjardins, A.; Quinn, J.A.; Vredenburgh, J.J.; Rich, J.N. Molecular targeted therapy for malignantglioma. Cancer, 2007, 110(1), 13-24.
10. Ho, L.J.; Chang, D.M.; Chang, M.L.; Kuo, S.Y.; Lai, J.H. Mechanismof immunosuppression of the antirheumatic herb TWHf inhuman T cells. J. Rheumatol., 1999, 26(1), 14-24.
11. Jang, B.C.; Lim, K.J.; Paik, J.H.; Cho, J.W.; Baek, W.K.; Suh, M.H.; Park, J.B.; Kwon, T.K.; Park, J.W.; Kim, S.P.; Shin, D.H.; Song, D.K.; Bae, J.H.; Mun, K.C.; Suh, S.I. Tetrandrine-inducedapoptosis is mediated by activation of caspases and PKC-aaain U937cells. Biochem. Pharmacol., 2004, 67(10), 1819-1829.
12. Chang, D.M.; Chang, W.Y.; Kuo, S.Y.; Chang, M.L. The effects of traditional antirheumatic herbal medicines on immune responsecells. J. Rheumatol., 1997, 24(3), 436-441.
13. Kondo, Y.; Takano, F.; Hojo, H. Inhibitory effect of bisbenzylisoquinolinealkaloids on nitric oxide production in activatedmacrophages. Biochem. Pharmacol., 1993, 46(11), 1887-1892.
14. Lin, T.Y.; Tseng, S.H.; Li, S.J.; Chen, J.C.; Shieh, J.S.; Chen, Y.Tetrandrine increased the survival rate of mice with lipopolysaccharide-induced endotoxemia. J. Trauma, 2009, 66(2), 411-417.
15. Chen, Y.; Wu, J.M.; Lin, T.Z.; Wu, C.C.; Chiu, K.M.; Chang, B.F.; Tseng, S.H.; Chu SH. Tetrandrine ameliorated reperfusion injury of small bowel transplantation. J. Pediatr. Surg., 2009, 44(11), 2145-2152.
16. Wang, G.; Lemos, J.R.; Iadecola, C. Herbal alkaloid tetrandrine: from an ion channel blocker to inhibitor of tumor proliferation.Trends Pharmacol. Sci., 2004, 25(3), 120-123.
17. Li, Y.Y.; Li, X.L.; Yang, C.X.; Zhong, H.; Yao, H.; Zhu, L. Effectsof tetrandrine and QYT on ICAM-1 and SOD gene expression inpancreas and liver of rats with acute pancreatitis. World J. Gastroenterol., 2003, 9(1), 155-159.
18. Li, S.Y.; Teh, B.S.; Seow, W.K.; Ling, L.H.; Thong, Y.H. Effect of tetrandrine on immunological response and cardiac transplant rejectionin mice. Int. Arch. Allergy Appl. Immunol., 1989, 90(2), 169-173.
19. Chen, Y.; Lai, H.S.; Chiang, B.L.; Tseng, S.H.; Chen, W.J. Tetrandrineattenuated dendritic cell-mediated alloimmune responses and prolonged graft survival in mice. Planta Med., 2010, Feb 25. [Epubahead of print] PMID: 20186657.
20. Lai, J.H.; Ho, L.J.; Lu, K.C.; Chang, D.M.; Shaio, M.F.; Han, S.H.Western and Chinese antirheumatic drug-induced T cell apoptoticDNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J. Immunol., 2001, 166(11), 6914-6924.
21. Huang, Y.T.; Cheng, Y.R.; Lin, H.C.; Chen, C.F.; Hong, C.Y.Haemodynamic effects of chronic tetrandrine treatment in portalhypertensive rats. J. Gastroenterol. Hepatol., 1997, 12(8), 585-589.
22. Xu, Y.; Rao, M.R. Effects of tetrandrine on left ventricle hypertrophyin deoxycorticosterone acetate-salt hypertensive rats. Eur. J.Pharmacol., 1995, 278(1), 1-7.
23. Lieberman, I.; Lentz, D.P.; Trucco, G.A.; Seow, W.K.; Thong, Y.H. Prevention by tetrandrine of spontaneous development of diabetesmellitus in BB rats. Diabetes, 1992, 41(5), 616-619.
24. Wang, H.L.; Kilfeather, S.A.; Martin, G.R.; Page, C.P. Effects of tetrandrine on growth factor-induced DNA synthesis and proliferativeresponse of rat pulmonary artery smooth muscle cells. Pulm.Pharmacol. Ther., 2000, 13(2), 53-60.
25. Zhang, Y.H.; Fang, L.H. Antagonism of morphine-induced antinociceptionby tetrandrine is dependent on serotonergic mechanism.Life Sci., 2001, 69(12), 1429-1439.
26. Liu, S.J.; Zhou, S.W.; Xue, C.S. Effect of tetrandrine on neutrophilicrecruitment response to brain ischemia/reperfusion. ActaPharmacol. Sin., 2001, 22(11), 971-975.
27. Liu, Z.; Xu, Z.; Shen, W.; Li, Y.; Zhang, J.; Ye, X. Effect of pharmacologicpreconditioning with tetrandrine on subsequent ischemia/reperfusion injury in rat liver. World J. Surg., 2004, 28(6), 620-624.
28. Shen, Y.C.; Chen, C.F.; Sung, Y.J. Tetrandrine amelioratesischaemia-reperfusion injury of rat myocardium through inhibitionof neutrophil priming and activation. Br. J. Pharmacol., 1999, 128(7), 1593-1601.
29. Chen, Y.J. Potential role of tetrandrine in cancer therapy. ActaPharmacol. Sin., 2002, 23(12), 1102-1106.
30. Chen, Y.; Chen, J.C.; Tseng, S.H. Effects of tetrandrine plus radiationon neuroblastoma cells. Anticancer Res., 2009, 29(8), 3163-3171.
31. Fu, L.W.; Zhang, Y.M.; Liang, Y.J.; Yang, X.P.; Pan, Q.C. Themultidrug resistance of tumour cells was reversed by tetrandrine invitro and in xenografts derived from human breast adenocarcinomaMCF-7/adr cells. Eur. J. Cancer, 2002, 38(3), 418-426.
32. Jin, Q.; Kang, C.; Soh, Y.; Sohn, N.W.; Lee, J.; Cho, Y.H.; Baik, H.H.; Kang, I. Tetrandrine cytotoxicity and its dual effect on oxidativestress-induced apoptosis through modulating cellular redoxstates in Neuro 2a mouse neuroblastoma cells. Life Sci., 2002, 71(17), 2053-2066.
33. Kuo, P.L.; Lin, C.C. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells. Life Sci., 2003, 73(2), 243-252.
34. Lai, Y.L.; Chen, Y.J.; Wu, T.Y.; Wang, S.Y.; Chang, K.H.; Chung, C.H.; Chen, M.L. Induction of apoptosis in human leukemic U937cells by tetrandrine. Anticancer Drugs, 1998, 9(1), 77-81.
35. Lee, J.H.; Kang, G.H.; Soh, Y.; Kim, K.M.; Park, D.I.; Choi, B.T.; Kang, H.S.; Lee, Y.T.; Choi, Y.H. Tetrandrine induced cell cyclearrest and apoptosis in A549 human lung carcinoma cells. Int. J.Oncol., 2002, 21(6), 1239-1244.
36. Liu, B.; Wang, T.; Qian, X.; Liu, G.; Yu, L.; Ding, Y. Anticancereffect of tetrandrine on primary cancer cells isolated from ascitesand pleural fluids. Cancer Lett., 2008, 268(1), 166-175.
37. Wu, J.M.; Chen, Y.; Chen, J.C.; Lin, T.Y.; Tseng, S.H. Tetrandrineinduces apoptosis and growth suppression of colon cancer cells inmice. Cancer Lett., 2010, 287(2), 187-195.
38. Han, X.; Wang, F.; Yao, W.; Xing, H.; Weng, D.; Song, X.; Chen, G.; Xi, L.; Zhu, J.; Xu, G.; Wang, S.; Meng, L.; Oadecola, C.; Wang, G.; Ma, D. Heat shock protein and p53 play a critical role inK+ channel-mediated tumor cell proliferation and apoptosis. Apoptosis, 2007, 12(10), 1837-1846.
39. Chang, K.H.; Chen, M.L.; Chen, H.C.; Huang, Y.W.; Wu, T.Y.; Chen, Y.J.l. Enhancement of radiosensitivity in human glioblastomaU138MG cells by tetrandrine. Neoplasma, 1999, 46(3), 196-200.
40. Chen, Y.; Chen, J.C.; Tseng, S.H. Tetrandrine suppresses tumorgrowth and angiogenesis of gliomas in rats. Int. J. Cancer, 2009, 124(10), 2260-2269.
41. Kuroda, H.; Nakazawa, S.; Katagiri, K.; Shiratori, O.; Kozuka, M.Antitumor effect of bisbenzylisoquinoline alkaloids. Chem. Pharm.Bull., 1976, 24(10), 2413-2420.
42. Chang, K.H.; Liao, H.F.; Chang, H.H.; Chen, Y.Y.; Yu, M.C.; Chou, C.J.; Chen, Y.J. Inhibitory effect of tetrandrine on pulmonarymetastases in CT26 colorectal adenocarcinoma-bearingBALB/c mice. Am. J. Chin. Med., 2004, 32(6), 863-872.
43. Sun, X.; Xu, R.; Deng, Y.; Cheng, H.; Ma, J.; Ji, J.; Zhou, Y. Effectsof tetrandrine on apoptosis and radiosensitivity of nasopharyngealcarcinoma cell line CNE. Acta Biochem. Biophys. Sin., 2007, 39(11), 869-878.
44. Yoo, S.M.; Oh, S.H.; Lee, S.J.; Lee, B.W.; Ko, W.G.; Moon, C.K.; Lee, B.H. Inhibition of proliferation and induction of apoptosis bytetrandrine in HepG2 cells. J. Ethnopharmacol., 2002, 81(2), 225-229.
45. Oh, S.H.; Lee, B.H. Induction of apoptosis in human hepatoblastomacells by tetrandrine via caspase-dependent Bid cleavage and cytochrome c release. Biochem. Pharmacol., 2003, 66(5), 725-731.
46. Ng, L.T. Antiproliferative and apoptotic effects of tetrandrine ondifferent human hepatoma cell lines. Am. J. Chin. Med., 2006, 34(1), 125-135.
47. Gross, A.; McDonnell, J.M.; Korsmeyer, S.J. Bcl-2 family membersand the mitochondria in apoptosis. Genes Dev., 1999, 13(15), 1899-1911.
48. Gross, A.; Jockel, J.; Wei, M.C.; Korsmeyer, S.J. Enforced dimerizationof Bax results in its translocation, mitochondrial dysfunctionand apoptosis. EMBO J., 1998, 17(14), 3878-3885.
49. Meng, L.H.; Zhang, H.; Hayward, L.; Takemura, H.; Shao, R.G.; Pommier, Y. Tetrandrine induces early G1 arrest in human commoncarcinoma cells by down-regulating the activity and inducingthe degradation of G1-S-specific cyclin-dependent kinases and byinducing p53 and p21Cip1. Cancer Res., 2004, 64(24), 9086-9092.
50. Chen, X.L.; Ren, K.H.; He, H.W.; Shao, R.G. Involvement of PI3K/AKT/GSK3beta pathway in tetrandrine-induced G1 arrestand apoptosis. Cancer Biol. Ther., 2008, 7(7), 1073-1078.
51. Nomura, M.; Yamazaki, R.; Takaya, M.; Kikuchi, M.; Takahashi-Nishioka, T.; Akiyama, K.; Akiyama, N.; Moritani, S.; Kobayashi, S. Inhibition of tetrandrine on epidermal growth factor-induced celltransformation and its signal transduction. Anticancer Res., 2007, 27(5A), 3187-3193.
52. English, J.; Pearson, G.; Wilsbacher, J.; Swantek, J.; Karandikar, M.; Xu, S.; Cobb, M.H. New insights into the control of MAPkinase pathways. Exp. Cell Res., 1999, 253(1), 255-270.
53. Tseng, S.H.; Lin, S.M.; Chen, J.C.; Su, Y.H.; Huang, H.Y.; Chen, C.K.; Lin, P.Y.; Chen, Y. Resveratrol suppresses the angiogenesisand tumor growth of gliomas in rats. Clin. Cancer Res. 2004, 10(6), 2190-3202.
54. Bulavin, D.V.; Philips, C.; Nannenga, B.; Timefeev, O.; Donehower, L.A.; Anderson, C.W.; Appella, E.; Fornace, A.J. Jr. Inactivationof the Wip1 phosphatase inhibits mammary tumorigenesisthrough p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet., 2004, 36(4), 343-350.
55. Manke, I.A.; Nguyen, A.; Lim, D.; Stewart, M.Q.; Elia, A.E.; Yaffe, M.B. MAPKAP kinase-2 is a cell cycle checkpoint kinasethat regulates the G2/M transition and S phase progression in responseto UV irradiation. Mol. Cell, 2005, 17(1), 37-48.
56. Cho, H.S.; Chang, S.H.; Chung, Y.S.; Shin, J.Y.; Park, S.J.; Lee, E.S.; Hwang, S.K.; Kwon, J.T.; Tehrani, A.M.; Woo, M.; Noh, M.S.; Hanifah, H.; Jin, H.; Xu, C.X.; Cho, M.H. Synergistic effectof ERK inhibition on tetrandrine-induced apoptosis in A549 humanlung carcinoma cells. J. Vet. Sci., 2009, 10(1), 23-28.
57. Liu, X.; Chang, Y.; Reinhart, P.H.; Sontheimer, H.; Chang, Y.Cloning and characterization of glioma BK, a novel BK channelisoform highly expressed in human glioma cells. J. Neurosci., 2002, 22(5), 1840-1849.
58. Ransom, C.B.; Liu, X.; Sontheimer, H. BK channels in humanglioma cells have enhanced calcium sensitivity. Glia, 2002, 38(4), 281-291.
59. Wu, S.N.; Lo, Y.K.; Li, H.F.; Shen, A.Y. Functional coupling of voltage-dependent L-type Ca2+ current to Ca2+-activated K+ currentin pituitary GH3 cells. Chin. J. Physiol., 2001, 44(4), 161-167.
60. Huang, M.H.; Wu, S.N.; Chen, C.P.; Shen, A.Y. Inhibition of Ca2+-activated and voltage-dependent K+ currents by 2-mercaptophenyl-1, 4-naphthoquinone in pituitary GH3 cells contribution to its antiproliferativeeffects. Life Sci., 2002, 70(10), 1185-1203.
61. Soroceanu, L.; Manning, T.J. Jr.; Sontheimer, H. Modulation of glioma cell migration and invasion using Cl- and K+ channel blockers.J. Neurosci., 1999, 19(14), 5942-5954.
62. Ghiani, C.A.; Yuan, X.; Eisen, A.M.; Knutson, P.L.; DePinho, R.A.; McBain, C.J.; Gallo, V. Voltage-activated K+ channels and membrane depolarization regulate accumulation of the cyclindependentkinase inhibitors p27Kip1 and p21CIP1 in glial progenitorcells. J. Neurosci., 1999, 19(13), 5380-5392.
63. Imoto, K.; Takemura, H.; Kwan, C.Y.; Sakano, S.; Kaneko, M.; Ohshika, H. Inhibitory effects of tetrandrine and hernandezine onCa2+ mobilization in rat glioma C6 cells. Res. Commun. Mol.Pathol. Pharmacol., 1997, 95(2), 129-146.
64. Wang, G.; Lemos, J.R. Tetrandrine: a new ligand to block voltagedependentCa2+ and Ca2+-activated K+ channels. Life Sci., 1995, 56(5), 295-306.
65. Wang, G.; Lemos, J.R. Tetrandrine blocks a slow, largeconductance, Ca(2+)-activated potassium channel besidew inhibitinga non0inactivating Ca2+ current in isolated nerve terminals of the rat neurohypophysis. Pflugers Arch., 1992, 421(6), 558-565.
66. Yan, C.; Xin-Ming, Q.; Li-Kun, G.; Lin-Lin, L.; Fang-Ping, C.; Ying, X.; Xiong-Fei, W.; Xiang-Hong, L.; Jin, R. Tetrandrineinducedapoptosis in rat primary hepatocytes is initiated from mitochondria: caspases and endonuclease G (Endo G) pathway. Toxicology, 2006, 218(1), 1-12.
67. Matthay, K.K.; Villablanca, J.G.; Seeger, R.C.; Stram, D.O.; Harris, R.E.; Ramsay, N.K.; Swift, P.; Shimada, H.; Black, C.T.; Brodeur, G.M.; Gerbing, R.B.; Reynolds, C.P. Treatment of highriskneuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid.Children's Cancer Group. N. Engl. J. Med., 1999, 341(16), 1165-1173.
68. Chen, Y.; Lin, T.Y.; Chen, J.C.; Yang, H.Z.; Tseng, S.H. GL331 (atopoisomerase II inhibitor) induces radiosensitization of humanglioma cells. Anticancer Res., 2006, 26(3A), 2149-2156.
69. Sun, X.C.; Cheng, H.Y.; Deng, Y.X.; Shao, R.G.; Ma, J. Tetrandrine: a potent abrogator of G2 checkpoint function in tumor cellsand its mechanism. Biomed. Environ. Sci., 2007, 20(6), 495-501.
70. Xie, X.; Sasai, K.; Shibuya, K.; Tachiiri, S.; Nihei, K.; Ohnishi, T.; Hiraoka, M. P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative. Cancer Chemother. Pharmacol., 2000, 45(5), 362-368.
71. Bases, R.; Mendez, F.; Franklin, W.A. Enhanced repair endonucleaseactivities from radiation-arrested G(2) phase mammalian cells.Int. J. Radiat. Biol., 1994, 65(5), 591-603.
72. Bunch, R.T.; Eastman, A. Enhancement of cisplatin-induced cytotoxicityby 7-hydroxystaurosporine (UCN-01), a new G2 checkpointinhibitor. Clin. Cancer Res., 1996, 2(5), 791-797.
73. Choi, S.U.; Park, S.H.; Kim, K.H.; Choi, E.J.; Kim, S.; Park, W.K.; Zhang, Y.H.; Kim, H.S.; Jung, N.P.; Lee, C.O. The bisbenzylisoquinolinealkaloids, tetrandrine and fangchinoline, enhance the cytotoxicityof multidrug resistance-related drug via modulation of Pglycoprotein.Anti-Cancer Drugs, 1998, 9(3), 255-261.
74. Zhu, X.; Sui, M.; Fan, W. In vitro and in vivo characterization of tetrandrine on the reversal of P-glycoprotein-mediating drug resistanceto paclitaxel. Anticancer Res., 2005, 25(3B), 1953-1962.
75. Liu, Z.L.; Hirano, T.; Tanaka, S.; Onda, K.; Oka, K. Persistentreversal of P-glycoprotein- mediated daunorubicin resistance bytetrandrine in multidrug-resistant human T lymphoblastoid leukemiaMOLT-4 cells. J. Pharmacy Pharmacol., 2003, 55(11), 1531-1537.
76. Tian, H.; Pan, Q.C. A comparative study on effect of two bisbenzylisoquinolines, tetrandrine and berbamine, on reversal of multidrug resistance. Acta Pharmacol. Sin., 1997, 32(4), 245-250.
77. He, Q.Y.; Jiang, B.; Zhang, H.Q.; Xue, S.B. Reversal of doxorubicinresistance in Chinese hamster ovary cell line. Acta Pharmacol.Sin., 1992, 13(5), 416-419.
78. He, Q.Y.; Meng, F.H.; Zhang, H.Q. Reduction of doxorubicinresistance by tetrandrine and dauricine in Harringtonine-resistanthuman leukemia (HL60) cells. Acta Pharmacol. Sin., 1996, 17(2), 179-181.
79. Wei, J.; Liu, B.; Wang, L.; Qian, X.; Ding, Y.; Yu, L. Synergisticinteraction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associatedgenes in human gastric cancer cell lines. Cancer Chemother.Pharmacol., 2007, 60(5), 703-711.
80. Dai, C.L.; Xiong, H.Y.; Tang, L.F.; Zhang, X.; Liang, Y.J.; Zeng, M.S.; Chen, L.M.; Wang, X.H.; Fu, L.W. Tetrandrine achievedplasma concentrations capable of reversing MDR in vitro and hadno apparent effect on doxorubicin pharmacokinetics in mice.Cancer Chemother. Pharmacol., 2007, 60(5), 741-750.
81. Xu, W.L.; Shen, H.L.; Ao, Z.F.; Chen, B.A.; Xia, W.; Gao, F.; Zhang, Y.N. Combination of tetrandrine as a potential-reversingagent with daunorubicin, etoposide and cytarabine for the treatmentof refractory and relapsed acute myelogenous leukemia. Leuk. Res., 2006, 30(4), 407-413.
82. Chaudhary, P.M.; Roninson, I.B. Expression and activity of Pglycoprotein, amultidrug efflux pump, in human hematopoieticstem cells. Cell, 1991, 66(1), 85-94.
83. Decleves, X.; Amiel, A.; Delattre, J.Y.; Scherrmann, J.M. Role of ABC transporters in the chemoresistance of human gliomas. Curr.Cancer Drug Targets, 2006, 6(5), 433-445.
84. Abe, T.; Mori, T.; Wakabayashi, Y.; Nakagawa, M.; Cole, S.P.; Koike, K.; Kuwano, M.; Hori, S. Expression of multidrug resistanceprotein gene in patients with glioma after chemotherapy. J.Neurooncol., 1998, 40(1), 11-18.
85. Bronger, H.; Konig, J.; Kopplow, K.; Steiner, H.H.; Ahmadi, R.; Herold-mende, C.; Keppler, D.; Nies, A.T. ABCC drug effluxpumps and organic anion uptake transporters in human gliomas and the blood-brain barrier. Cancer Res., 2005, 65(24), 11419-11428.
86. Tews, D.S.; Nissen, A.; Kulgen, C.; Gaumann, A.K. Drug resistance-associated factors in primary and secondary glioblastoma and their precursor tumors. J. Neurooncol., 2000, 50(3), 227-237.
87. Caltagirone, S.; Rossi, C.; Poggi, A.; Ranelletti, F.O.; Natali, P.G.; Brunetti, M.; Aiello, F.B.; Piantelli, M. Flavonoid apigenin and quercetin inhibit melanoma growth and metastatic potential. Int. J.Cancer, 2000, 87(4), 595-600.
88. Friedlander, M.; Brooks, P.C.; Shaffer, R.W.; Kincaid, C.M.; Varner, J.A.; Cheresh, D.A. Definition of two angiogenic pathwaysby distinct αV integrins. Science, 1995, 270(5241), 1500-1502.
89. Plate, K.H.; Breier, G.; Weich, H.A.; Risau, W. Vascular endothelialgrowth factor is a potential tumor angiogenesis factors in humangliomas in vivo. Nature, 1992, 359(6398), 845-848.
90. Kobayashi, S.; Kimura, I.; Fukuta, M.; Kontani, H.; Inaba, K.; Niwa, M.; Mita, S.; Kimura, M. Inhibitory effects of tetrandrineand related synthetic compounds on angiogenesis in streptozotocindiabeticrodents. Biol. Pharm. Bull., 1999, 22(4), 360-365.
91. Wu, S.N.; Li, H.F.; Lo, Y.C. Characterization of tetrandrineinducedinhibition of large-conductance calcium-activated potassiumchannels in a human endothelial cell line (HUV-EC-C). J.Pharmacol. Exp. Ther., 2000, 292(1), 188-195.
92. DeLisser, H.M.; Christofidou-Solomidou, M.; Strieter, R.M.; Burdick, M.D.; Robinson, C.S.; Wexler, R.S.; Kerr, J.S.; Garlanda, C.; Merwin, J.R.; Madri, J.A.; Albelda, S.M. Involvement of endothelialPECAM-1/CD31 in angiogenesis. Am. J. Pathol., 1997, 151(3), 671-677.
93. Gralla, E.J.; Coleman, G.L.; Jonas, A.M. Toxicology studies withd-tetrandrine (NSC-77037), a plant alkaloid with vascular and lymphotoxiceffects in dogs and monkeys. Cancer Chemother. Rep. 3, 1974, 5(1), 79-85.
94. Herman, E.H.; Chadwick, D.P. Cardiovascular effects of d-Tetrandrine. Pharmacology, 1974, 12(2), 97-109.
95. Wong, C.W.; Seow, W.K.; Thong, Y.H. Comparative effects of tetrandrine and berbamine on acute and relapsing experimental allergic encephalitis in Lewis rats. Int. Arch. Allergy Appl. Immunol., 1992, 97(1), 31-36.
96. Xiao, J.; Wu, S.; Wang, Y.; Li, J.; Zhang, S. Inhibitory effects of tetrandrine on bovine serum albumin-induced uveitis in rabbits. J.Ocular Pharmacol., 1993, 9(2), 151-156.
97. Qian, J.Q.; Thoolen, M.J.; van Meel, J.C.; Timmermans, P.B.; van Zwieten, P.A. Hypotensive activity of tetrandrine in rats. Investigationinto its mode of action. Pharmacology, 1983, 26(4), 187-197.
98. Wong, T.M.; Wu, S.; Yu, X.C.; Li, H.Y. Cardiovascular actions of Radix Stephaniae Tetrandrae: a comparison with its main component, tetrandrine. Acta Pharmacol. Sin., 2000, 21(12), 1083-1088.
99. Kwan, C.Y.; Chen, Y.Y.; Ma, M.F.; Daniel, E.E.; Hui, S.C.G.Tetrandrine, a calcium antagonist of Chinese herbal origin, interactswith vascular muscle ww1-adrenoceptor. Life Sci., 1996, 59(23), 359-364.
100. Hait, W.N. Anticancer drug development: the grand challenges.Nat. Rev. Drug Discov., 2010, 9(4), 253-254.
101. Huse, J.T.; Holland, E.C. Targeting brain cancer: advances in themolecular pathology of malignant glioma and medulloblastoma.Nat. Rev. Cancer, 2010, 10(5), 319-331.
102. Li, R.; Li, X.; Xie, L.; Ding, D.; Hu, Y.; Qian, X.; Yu, L.; Jiang, X.; Liu, B. Preparation and evaluation of PEG-PCL nanoparticlesfor local tetrandrine delivery. Int. J. Pharm., 2009, 379(1), 158- 166.